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Certain covalently linked insulin dimers have previously been found to have a greater ability to bind to 
the insulin receptor than to stimulate lipogenesis in adipocytes. The present report presents data indicating 
that the same insulin dimers also have a greater ability to bind to the receptor than to stimulate the kinase 
activity of the insulin receptor. In particular, one such covalently linked insulin dimer had less than 1% 
the potency of native insulin in stimulating the receptor kinase although it could bind to the solubilized 
receptor with 30% the potency of native insulin. In contrast, this dimer could down regulate the insulin 
receptor with approximately 30% the potency of native insulin. These results suggest hat stimulation of 
the receptor kinase may require more than simple occupancy of the receptor binding site whereas down 
regulation of the receptor may require only the binding of ligand to the receptor. 
Hormone receptor Phosphorylation Insulin action 
1. INTRODUCTION 
Insulin binds to a specific receptor protein on 
the surface of target cells and initiates a variety of 
biological responses [ 1,2]. Recently, authors in [31 
reported that the binding of insulin to the receptor 
stimulates the extent of phosphorylation of the 
receptor. Furthermore, several studies have in- 
dicated that the insulin receptor is itself a protein 
kinase and that insulin stimulates this kinase activi- 
ty of the receptor [4-81. Since several effects of in- 
sulin are mediated via phosphorylation-dephos- 
phorylation reactions [9- 121, it has been 
hypothesized that the activation of the kinase ac- 
tivity of the receptor is the first step in initiating 
the response of the cell to the hormone. Alter- 
natively, it has been hypothesized that the kinase 
Abbreviations: Bl-B ’ 29D, NB’,NB ’ 29-suberoyl-insulin 
dimer; Bl-B’ lD, NB’,NB”-suberoyl-insulin dimer; 
B29-B’ 29D, NB29,NB ’ 29-suberoyl-insulin dimer 
activity of the receptor is important in mediating 
the insulin-induced decrease in hormone receptor 
binding, the phenomenon termed receptor down 
regulation [13-151. 
To test these hypotheses, we have examined the 
ability of several covalently linked insulin dimers 
to regulate the kinase activity of purified insulin 
receptor and to down regulate the receptor. These 
dimers were prepared by crosslinking insulin 
monomers with a suberoyl chain at either the Bl 
Phe or B29 Lys [ 161. The resulting 3 dimers 
(Bl-B’ lD, Bl-B’29D, and B29-B’29D) are of in- 
terest because of their unusual properties; the abili- 
ty of these dimers to inhibit the binding of [i2’I]in- 
sulin to its receptor on either rat liver plasma mem- 
branes or adipocytes is 25fold (for Bl-B’29D) to 
7-fold (for B29-B’29D) greater than their abilities 
to stimulate lipogenesis in adipocytes [ 16-181. 
These discrepancies in binding and biological 
potencies of the covalent insulin dimers make them 
useful tools for studying the relationship between 
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the binding of insulin to its receptor and the subse- 
quent events in insulin action. 
2. MATERIALS AND METHODS 
The following were purchased: porcine insulin 
(27.30 SP units per mg) from Elanco; wheat germ 
agglutinin coupled to agarose from Miles; N- 
acetyl-D-glucosamine, phenylmethylsulfonyl flu- 
oride (PMSF) and bacitracin from Sigma; adenos- 
ine 5 ’ -ly-32P]triphosphate (ATP) (16 Ci/mmol) 
from Amersham; and Affi-Gel 15 and gel reagents 
from Bio Rad. 
The synthesis of the insulin dimers was as in 
[ 161. The monoclonal antibody was prepared as in 
[ 191. The [“‘I]insulin was prepared by a 
stoichiometric chloramine T method [19] to a 
specific activity of 130 Ci/g. 
2.1. Purification of the insulin receptor 
Insulin receptors were purified from human 
placenta as follows: after removal of the amnion 
and chorion, the placenta was cut into small 
fragments and frozen in liquid nitrogen. Thirty 
gram portions were thawed and homogenized in a 
Brinkman Polytron in 60 ml of 1% Triton X-100 
in 50 mM Hepes containing 1 mM PMSF and 
1 mglml of bacitracin. The insoluble material was 
removed by successive centrifugations of 20 min at 
20000 x g and 60 min at 100000 x g. The superna- 
tant was passed over an 8 ml column of 
monoclonal anti-receptor antibody coupled to 
Affi-Gel 15 1141. The column was washed with 
50 ml of 50 mM Hepes (pH 7.6), 150 mM NaCl, 
0.1% Triton X-100, 1 mM PMSF and 1 mg/ml 
bacitracin, then 20 ml of the same buffer with the 
addition of 1 M NaCl, and then the receptor was 
eluted with 1.5 M MgCL in 120 mM borate buffer 
(pH 6.5) with 0.1% Triton X-100. The eluted 
receptor was immediately diluted lo-fold and fur- 
ther purified on a 5 ml wheat germ agglutinin af- 
finity column 141. For the experiments utilizing 
purified receptor, two separate receptor prepara- 
tions were utilized. 
2.2. Receptor kinase assays 
The purified receptor was incubated for 60 min 
at 24°C in 30~1 of a buffer containing 50 mM 
Hepes (pH 7.6), 0.1% Triton X-100, 150 mM 
NaCl, 2 mM MnClt and the indicated insulin 
dimer. Then 5-8 FM [Y-~~P]ATP (16 Ci/mmol) 
was added and the reaction was allowed to proceed 
for 60 min at 24°C. Under these conditions, the 
phosphorylation of the receptor increased linearly 
for 60 min at 24°C and no significant ATP 
hydrolysis could be detected. The samples were 
then made 1% in SDS and 5% in mercaptoethanol, 
heated to 100°C for 1 min and electrophoresed on 
a 7.5% polyacryl~ide gel [ 191, The gel was 
stained, dried, the p-subunit band identified by 
autoradiography and the appropriate portion of 
the gel was excised and the radioactivity deter- 
mined in a liquid scintillation counter. 
2.3. Receptor birding assays 
Binding assays were performed with both 
purified receptor and intact IM-9 lymphocytes. 
For the purified receptor assay, the assay was per- 
formed exactly as described for the kinase assay 
except that 100 pM [‘2sI]insulin was included in 
the reaction in place of ATP. After 2 h at 24°C 
the receptor was precipitated with 10.5% 
polyethylene glycol in the presence of carrier 
human 7 globulin (1 mg/ml). The pellets (5 min at 
10000 x g in a Beckman microfuge) were washed 
twice with 10.5% polyethylene glycol and counted. 
Non-specific binding was determined in the 
presence of 10m5 M insulin and subtracted. 
The binding assay with IM-9 cells was per- 
formed essentially as in [19]. In brief, IM-9 cells (5 
x ld) in ZOO/r1 minimal Eagle’s medium with 
50 mM Hepes were incubated for 70 min at 15°C 
with the dimers and 40 pM [12sIJinsulin. The cells 
were cooled to 4’C, centrifuged (200 x g for 
10 min) and washed twice. The pellets were 
counted and non-specific binding (that bound in 
the presence of 10m5 M insulin) was subtracted. 
2.4. Receptor down regulation 
IM-9 cells (5 x 10’ cells/ml) were incubated in 
normal growth media (minimal Eagle’s medium 
with 1OVo fetal calf sera, 20 mM Hepes (pH 7.4) 
and non-essential amino acids) with the insulin 
dimers for 18 h at 37°C. The cells were harvested 
by centrifugation and extensively washed as in 
[14]. In brief, this wash procedure includes two in- 
cubations of 25 min at 30°C at pH 6.0 and three 
washing steps to allow the dissociation of bound 
ligands. The ability of the washed cells to bind 
[‘251]insulin was then measured by resuspending 
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the cells in binding buffer (100 mM Hepes (pH 
7.8), 1.20 mM NaCl, 1.2 mM MgS04, 1 mM 
EDTA, 15 mM sodium acetate, 10 mM glucose 
and 1% bovine serum albumin) and 70 pM [12?]- 
insulin. After 70 min at 15”C, the cells were wash- 
ed and the radioactivity in the cell pellet was 
measured. Non-specific binding, determined by in- 
cluding 10 /IM unlabeled insulin, was subtracted to 
give specific binding. 
3. RESULTS 
3.1. Receptor binding ability of the insulin dimers 
The insulin dimers were tested for their ability to 
inhibit the binding of [‘251]insulin to its receptor on 
IM-9 cells (fig.1). The concentrations of insulin 
and the dimers Bl-B’29, B29-B’29, and Bl-B’l 
required to inhibit 50% of the binding (the ZW) 
were 400, 300, 400 and 1100 pM, respectively. 
These values for the dimers (in particular, Bl-B’ 1) 
are less than those previously reported since the 
short incubation times which were chosen to mimic 
the kinase assay are not sufficient to reach 
equilibrium for the dimers [18]. 
The dimers were also tested for their ability to 
inhibit the binding of [‘251]insulin to purified, 
solubilized receptor under conditions identical to 
the kinase assays described below. In this assay, 
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Fig.1. Receptor binding potencies of the insulin dimers. 
IM-9 cells were incubated with the indicated 
concentration of insulin dimers and 40 pM [‘251]insulin 
for 70 min at 15°C. The cells were then washed and the 
radioactivity bound was counted. Each point is the 
average of 6 determinations from 2 independent 
experiments and the standard errors for each value were 
Fig.2. Stimulation of receptor kinase by insulin dimers. 
Purified insulin receptor was preincubated with the 
indicated concentrations of dimers or insulin for 60 min 
at 24”C, and then the reaction was started by the 
addition of 10pM [Y-~~P]ATP. After 60 min at 24”C, 
the reaction was stopped by heating the samples at 
100°C with 1% SDS. The samples were electrophoresed 
and the gels were processed as in [4]. The&subunit band 
was excised and the radioactivity in this band determined 
and shown in the figure. Two additional experiments 
utilizing different receptor preparations gave 
comparable results. The average relative potency for the 
dimers Bl-B’29, Bl-B’l and B29-B’29 were 30070, 10% 
less than 10% of the values. and less than 1% that of insulin, respectively. 
the concentrations of insulin and the dimers 
Bl -B’29, B29-B’29 and Bl-B’ 1 required to inhibit 
50% of the binding were 2.7, 2.3, 7.3 and 17 nM, 
respectively. 
3.2. Stimulation of receptor kinase activity by the 
insulin dimers 
The insulin dimers were then tested for their 
ability to stimulate the phosphorylation of the p- 
subunit of the purified receptor (fig.2). The 
Bl -B ’ 29 dimer had the greatest ability to stimulate 
the receptor kinase activity (approximately half 
that of insulin), Bl-B’l dimer was next and 
B29-B’29 dimer had the weakest ability to 
stimulate the receptor kinase (less than 1% that of 
native insulin). 
3.3. Down regulation of the insulin receptor by the 
dimers 
The dimers were then tested for their ability to 
regulate the expression of the insulin receptor. 
Prior studies have shown that preincubation of 
IM-9 cells with insulin causes a dose-dependent 
? 
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Fig.3. Down regulation of the insulin receptor of IM-9 
cells by insulin dimers. IM-9 cells were incubated for 
18 h at 37°C with the indicated concentrations of insulin 
dimers. The cells were then extensively washed and 
tested for their ability to bind [‘251]insulin. The rest&s 
shown are averages of 6 determinations from 2 
independent experiments and the standard errors for 
each value were less than 1OVo of the values. 
decrease in the subsequent ability of these cells to 
bind insulin, the phenomenon termed down regu- 
lation [13-151. The Bl-B’29 dimer was found to 
be the best at down regulating the insulin receptor, 
B I-B’ 1 was next and B29-B ‘29 had the weakest 
ability (approximately l/3 that of insulin) (fig.3). 
4. DISCUSSION 
Prior studies have indicated a discrepancy bet- 
ween the ability of covalently linked insulin dimers 
to bind to the insulin receptor and to stimulate 
lipogenesis {16-181. This discrepancy was most 
pronounced with the dimer B29-B’29. The present 
data indicate that this dimer also exhibited the 
greatest discrepancy between its ability to bind to 
the receptor and its ability to stimulate the receptor 
kinase. Although it inhibited [“251]insulin binding 
to IM-9 cells with approximately the same potency 
as native insulin, it had less than 1070 the potency 
of native insulin in stimulating the receptor kinase. 
This discrepancy was observed even when binding 
ability was assessed using the same purified recep- 
tor system as used for the kinase assays. These 
results indicate that the binding of this molecule to 
the receptor does not induce the necessary change 
in the state of the receptor which is needed for the 
activation of the receptor kinase. This change in 
the state of the receptor could be a conformations 
change [20] or a change in the sulfhydryl status of 
the receptor [21). 
In contrast to the weak potency of the B29-B’29 
dimer in stimulating the receptor kinase, this dimer 
was approximately 30% as potent as native insulin 
at down regulating the insulin receptor of IM-9 
cells. This result is consistent with the hypothesis 
that receptor occupancy is sufficient for down 
regulation of the receptor. This conclusion is also 
supported by the finding that the insulin receptor 
can be down regulated by an antagonist of insulin, 
a rnonoclonal anti-receptor antibody [22]. 
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